Papillary thyroid carcinoma (PTC) has an excellent prognosis with a relatively low mortality rate, but a small portion of PTC patients suffer from an aggressive form of the disease. In such cases early detection of lymph node metastasis (LNM) is as paramount as it is problematic.The routine use of central neck lymph node dissection is not recommended. New methods to detect LNM are needed. MicroRNAs are a potential biomarker for diagnosis and prognosis of PTC. In this review we summarise the current knowledge regarding dysregulated miRNAs and their association with LNM in PTS patients. The PubMed and EBSCO databases were searched using terms for "microRNA", "thyroid carcinoma", and "prognosis" by using Boolean operators. Based on eligibility and exclusion criteria, articles were screened and reviewed in full, methodological data of included studies were extracted, and risk of bias analysis performed. In total, 446 unique studies were extracted from the mentioned databases, and based on inclusion and exclusion criteria 27 studies were included in this review. Of them 17 analysed tissue microRNAs, 5 analysed circulating microRNAs, and 5 studies analysed both tissue and circulating samples. were dysregulated in at least 2 separate studies. A sizable portion of studies failed to show statistically significant differences in miRNA expression between LNM-positive and -negative patients. Different methodologies and disparities of patient populations could explain these discrepancies. This research supports the statement that specific up-and downregulated miRNAs are associated with LNM in PTC patients. However, the prognostic value of these miRNAs is limited. Additional targeted cohort studies are required to elucidate the role of miRNAs in defining individualised treatment strategies for thyroid cancer patients.
Background: Primary thyroid lymphoma is a rare thyroid disease that makes up only 1 to 5% of all thyroid oncological disorders. The average patient with primary thyroid lymphoma is a woman in her sixth or seventh decade with a history of Hashimoto’s thyroiditis. Clinical Case: 28-year-old woman complained of hoarseness, rapidly enlarging mass of the neck. She was referred to an otorhinolaryngologist by her family physician who suspected upper airway pathology. Otorhinolaryngologist observed swelling of patients’ larynx and prescribed treatment for suspected bacterial larynx infection. Symptoms kept worsening despite of treatment and patient was referred to an endocrinologist for a consultation. Blood lab tests were unremarkable. Ultrasound of the thyroid was performed which revealed a large (4,5 cm), hypoechoic, solid, homogenous node with Doppler signs of increased intranodular vascularity. Additionally, enlarged submandibular salivary gland lymph nodes on both sides of the neck were observed. FNAC (fine-needle aspiration cytology) was performed to diagnose possible thyroid malignancy, however findings showed atypia of undetermined significance (3rd category of Bethesda classification), to differentiate from lymphocytic thyroiditis. Because of high risk of malignancy, it was decided to perform thyroidectomy. During surgery, urgent intraoperative biopsy revealed undifferentiated thyroid carcinoma. As radical tumor extirpation due to prominent surrounding fibrosis was impossible, then only one side lobectomy was performed. Final histological examination revealed large B cell lymphoma, phenotype: CD20+, BCL6+, MuM1+, CD21+, cMyc-, BCL2-, CD10-, CD30-, Ki-67 up to 97%. More accurate disease staging was performed post-operatively, PET scan and computed tomography revealed disseminated primary thyroid lymphoma. Final diagnosis was Stage IV primary large B cell lymphoma of the thyroid. Patient was treated with chemotherapy according to Rx7-CHOP14x6 (Rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) protocol. The treatment was tolerated well, 3 months after, complete remission of the disease was observed. During outpatient visits patient remained in remission for all 5 years of planned regular check-ups. Conclusion: This case demonstrates the diagnostic challenge of primary thyroid lymphoma. In the presence of rapidly enlarging thyroid mass, thyroid lymphoma is not usually suspected. FNAC as golden standard of thyroid malignancy often does not allow differentiation of this pathology. In this case, a core biopsy could have helped to make correct preoperative diagnosis and to avoid unnecessary surgery.
The aim of the study was to evaluate the diagnostic utility of specific miRNAs in the preoperative assessment of thyroid nodules. One hundred and sixty thyroid fine needle aspiration biopsy (FNAB) samples with suspected thyroid carcinoma were collected. To detect the levels of miRNA expression in FNAB, next generation small RNA sequencing was performed in 60 samples. Based on the results obtained, three miRNAs (miR125A, miR200B, miR4324) were selected for further analysis. Based on the most frequently reported miRNAs in the literature associated with thyroid papillary carcinoma (PTC), two more miRNA (miR146B, miR221) were selected for further validation, using real-time reverse transcriptase polymerase chain reaction (RT-PCR) in 36 benign and 64 PTC samples. Expression of miR125A, miR146B, miR221, and miR4324 was significantly higher in patients with PTC compared with benign thyroid nodules (p ˂ 0.05). miR125A and miR4324 were also significantly more highly expressed in patients with extrathyroidal tumor extension compared to those without extrathyroidal PTC extension (p < 0.001). We also found a significantly higher expression of miR221 (p = 0.043) in patients with multifocal carcinomas compared to patients with single foci carcinomas. This prospective study showed that the expression analysis of four miRNAs (miR125A, miR146B, miR221, and miR4324) improve accuracy of FNAB, which could allow a better pre-operative diagnostic and prognostic assessment of thyroid malignancies.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.